Healthcare professionals use AMH as an important fertility marker to assess ovarian reserve levels.
Compared to the follicle-stimulating hormone (FSH) and estradiol, the AMH blood test is claimed to be a superior indicator of ovarian reserve and it can be measured during any day of the menstrual cycle.
In addition, the Elecsys AMH blood test produces standardised results for evaluating ovarian reserve as compared with the use of ultrasound, with the result often dependent on the operator or clinic.
Roche Diagnostics chief operating officer Roland Diggelmann said: "The introduction of our Elecsys AMH test will enable healthcare professionals to incorporate AMH testing into routine clinical practice while getting more reliable results faster than conventional protocols and manual AMH assays.
"It is an important example of our focus on improving diagnostics in the area of women’s health."
The test will be available in all markets accepting the CE Mark in Europe, Latin America, Middle East, Africa and Asia, while it is currently not available in the US and Japan.
In future, the company intends to use the Elecsys AMH test in combination with the new human recombinant follicle-stimulating hormone (human rFSH) treatment, which is currently in Phase III development at Ferring Pharmaceuticals.
The combination is expected to provide an improved option for couples seeking to conceive through in vitro fertilisation.
Around 80 million people across the globe are facing fertility issues, according to the World Health Organization (WHO).
The company said that the combination will make possible individualised dosing of human rFSH based on a woman’s specific AMH level.